Article and Video CATEGORIES
First Line Regiments of Pembrolizumab Monotherapy vs. Pembrolizumab and Chemo for Patients with Recurrent or Metastatic HNSCC

We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials.
Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE chaired this program.
Drs. Bauml and Weiss spoke with Dr. Kathryn Gold, Medical Oncologist and Associate Professor of Medicine at the University of California San Diego and Dr. Ranee Mehra, Professor of Medical Oncology at the University of Maryland, on the newest updates to 2020 trials and studies presented at ASCO and ESMO this year.
For this discussion, Drs. Bauml, Weiss, Gold and Mehra discuss what we have learned from Keynote 048: First Line Regiments of Pembrolizumab Monotherapy vs. Pembrolizumab and Chemo for Patients with Recurrent or Metastatic HNSCC
We thank Varian for their support of this program!
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.
Glad to help. FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/
Hope to see...